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Plaque vulnerableAngiotensin (Ang) II contributes to the development of atherosclerosis,while Ang-(1–7) has atheroprotective ac-
tions. Accordingly, angiotensin-converting enzyme 2 (ACE2), which breaks-down Ang II and forms Ang-(1–7),
has been suggested as a target against atherosclerosis. Herewe investigated the actions of diminazene, a recently
developed ACE2 activator compound, in amodel of vulnerable atherosclerotic plaque. Atherosclerotic plaque for-
mation was induced in the carotid artery of ApoE-deﬁcient mice by a shear stress (SS) modiﬁer device. The an-
imals were treated with diminazene (15 mg/kg/day) or vehicle. ACE2 was strongly expressed in the aortic root
and low SS-induced carotid plaques, but poorly expressed in the oscillatory SS-induced carotid plaques.
Diminazene treatment did not change the lesion size, but ameliorated the composition of aortic root and low
SS-induced carotid plaques by increasing collagen content and decreasing both MMP-9 expression and macro-
phage inﬁltration. Interestingly, these beneﬁcial effects were not observed in the oscillatory SS-induced plaque.
Additionally, diminazene treatment decreased intraplaque ICAM-1 and VCAM-1 expression, circulating cytokine
and chemokine levels and serum triglycerides. In summary, ACE2 was distinctively expressed in atherosclerotic
plaques, which depends on the local pattern of shear stress. Moreover, diminazene treatment enhances the
stability of atherosclerotic plaques.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
Vulnerable plaque, characterized by the presence of intense inﬂam-
mation and a lipid-rich necrotic core covered by a thin ﬁbrous cap, have
a higher propensity to rupture and lead to subsequent thrombotic
occlusion. Indeed, it iswell recognized that the risk of thrombosis in ath-
erosclerosis largely depends on plaque composition [1,2].
Local shear stress forces have been documented as a biomechanical
factor which modulates atherogenesis and plaque composition [3–5].
For instance, it has been shown that local low shear stress (LSS)may in-
duce plaque formation and a vulnerable composition [5]. Severalmolec-
ular pathways are involved in the shear-stress inducing plaque
vulnerability process; however, such mechanisms are poorly known.ynamics and Cardiovascular
hnique Fédérale de Lausanne,
Silva).The renin–angiotensin system (RAS), amajor regulator of cardiovas-
cular function, is highly involved in the genesis and progression of ath-
erosclerosis [6–8].Moreover, this system seems to actively inﬂuence the
composition of atherosclerotic plaques. Angiotensin (Ang) II, the main
effector of RAS, contributes to atherosclerosis development by increas-
ing vascular permeability, inﬂammatory cell inﬁltration and LDL
oxidation and uptake [9–11]. Moreover, Ang II may increase plaque vul-
nerability bymodulatingmacrophage trapping, increasing reactive oxy-
gen species production and weakening the ﬁbrous cap by activation of
matrix metalloproteinase (MMP) [10,12,13].
Contrarily to Ang II, emerging data indicates that Ang-(1–7), another
effector of RAS, has atheroprotective actions [14–16]. It has been shown
that Ang-(1–7) infusion promotes a reduction in plaque size and im-
proves vascular endothelial function in hypercholesterolemic mice
[17]. Moreover, long-term treatment with Ang-(1–7) enhances athero-
sclerotic plaque stability by increasing intraplaque collagen content, de-
creasing MMP-9 expression and reducing neutrophil and macrophage
inﬁltration [18].
Fig. 1.ACE2 is distinctively expressedwithin atherosclerotic plaque depending on the local pattern of shear stress. Immunolocalization of ACE2 in LSS- andOSS-induced plaques and aortic
sinus plaques. Representative microphotographs of diminazene- and vehicle-treated ApoE−/−mice are shown. Positive staining is shown in brown color. The negative control (NC) is
shown in the upper right panels. No difference in ACE2 expression was observed between treated or non-treated mice.
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and Ang-(1–7) levels. This enzyme breaks-down Ang II, by cleaving the
C-terminal phenylalanine and, consequently, forms Ang-(1–7);
therefore, ACE2 reduces Ang II and favors Ang-(1–7) actions [19].
ACE2 enzyme is expressed in animal models [20] and human [21]
atherosclerotic plaques, playing a protective role in atherosclerosis
[14]. Indeed, ACE2 overexpression attenuates the progression of athero-
sclerotic lesions and increases plaque stability [22]. Contrarily, ACE2 de-
ﬁciency in low-density lipoprotein receptor (Ldlr−/−) or apolipoprotein
E (ApoE−/−)-deﬁcient mice worsens atherogenesis [23–25]. Based on
these observations, ACE2 has being suggested as a potential target for
the treatment of atherosclerosis.
In the present study, an investigation on the effects of diminazene
(a recently developed pharmacological ACE2 activator) [26,27], in a
mouse model of vulnerable atherosclerotic plaque was performed.
2. Methods
2.1. Experimental design
The atherosclerotic plaques were induced within the right carotid
artery of ApoE−/− mice by modifying the local pattern of shear stressFig. 2. ADAM17 expression is not different between LSS- and OSS-induced plaques. A–D) Micr
showingDAPI (A) and ADAM17 (B); andOSS-induced plaque showing DAPI (C) and ADAM17 (
E) Quantiﬁcation for ADAM17 expression. n.s.: non-signiﬁcant (Mann–Whitney nonparametri[5]. ApoE−/−micewith a C57BL/6J background (n=40)were obtained
from Jackson Laboratories (LesOncins, France). Animals at 15–20weeks
received western-type diet consisting of 15% (wt/wt) cocoa butter and
0.25% (wt/wt) cholesterol (Diet W; abDiets) for the entire 11 week
experimental period. After 2 weeks of adaptation to the western-type
diet, speciﬁc patterns of shear stresswere applied to the right carotid ar-
tery by the surgical placement of a shear stress modiﬁer device called
“cast”. The cast consists of 2 longitudinal halves of a cylinder with a
cone-shaped lumen, which imposes a ﬁxed geometry on the vessel
wall. Such geometry produces vortices downstream, therefore exposing
the artery wall to oscillatory shear stress (OSS) in the downstream re-
gion and a low shear stress (LSS) in the region upstream of the blood
ﬂow [5,28]. Such distinct patterns of shear stress induce atherosclerotic
plaques with different compositions. LSS-induced plaques present
features of vulnerable plaques, whereas OSS-induced plaques display a
more stable phenotype [5,18,28,29].
The cast was implanted as previously described [18,29]. Brieﬂy, the
animals were anesthetized by isoﬂurane inhalation, and the anterior
cervical triangles were accessed by a sagittal anterior neck incision.
The right carotid artery was carefully detached from connecting tissue
and, sequentially, the cast halves were placed around and ﬁxed with
silk suture. After closing the wounds, the animals were allowed toophotographs of carotid artery lesion from untreated ApoE−/−mice: LSS-induced plaque
D). The negative control (NC) is shown in the lower right portion of eachmicrophotograph.
c test). Data were expressed as mean ± SEM.
Fig. 3.Macrophage and neutrophil are not themean source of ACE2 intraplaque.Microphotographs of LSS-induced plaques. A–D) It shows the co-immunostaining for CD68 (macrophage
marker) andACE2. In sequence: A)DAPI; B) CD68; C)ACE2; andD)merged image fromCD68andACE2. E–H) It shows the co-immunostaining for Ly6B.2 (neutrophilmarker) andACE2. In
sequence: E) DAPI; B) Ly6B.2; C) ACE2; and D) merged image from Ly6B.2 and ACE2.
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mice were randomly assigned to receive either vehicle or diminazene
[15 mg/kg per day] subcutaneously. After 9 weeks after of cast implan-
tation (a total of 11 weeks' feeding with western diet), the mice were
anesthetized (ketamine 100mg/kg, xylazine 10mg/kg) and blood sam-
ples were collected by cardiac puncture. Immediately following cardiacFig. 4. Diminazene treatment did not alter lipid intraplaque accumulation. Quantiﬁcation fo
plaques (C) of diminazene- and vehicle-treated ApoE−/− mice. n.s.: non-signiﬁcant (Mann
microphotographs (D).puncture, the animals were perfused with PBS and the carotid artery
aortic roots removed and frozen in a cryoembeddingmedium for histo-
logical analysis. The entire aortas were dissected from the ascending
portion until the bifurcation of the iliac arteries and ﬁxed in 4% parafor-
maldehyde for 24 h for atherosclerotic lesion analyses. This animal
study was approved by local ethics committee and Swiss Regulatoryr lipid staining in: LSS-induced plaques (A); OSS-induced plaques (B) and aortic sinus
–Whitney nonparametric test). Data were expressed as mean ± SEM. Representative
Table 1
Serum lipid proﬁle.
Mouse proﬁle Vehicle
(n = 12)
DIZE
(n = 10)
p-Value
Body weight day 0 (g) 24.16 ± 0.43 24.67 ± 0.51 0.4491
Body weight at sacriﬁce (g) 32.29 ± 0.52 33.10 ± 0.56 0.3045
Oil Red O in the aorta (% of total area) 7.27 ± 0.93 8.66 ± 2.08 0.5337
Total cholesterol (mmol/L) 25.76 ± 1.97 25.55 ± 2.13 0.9440
HDL (mmol/L) 4.881 ± 0.307 4.953 ± 0.459 0.8940
LDL (mmol/L) 21.11 ± 1.58 21.66 ± 2.02 0.8297
Triglycerides (mmol/L) 0.894 ± 0.088 0.631 ± 0.041 0.0343⁎
Free fatty acids (mmol/L) 0.588 ± 0.061 0.653 ± 0.066 0.4968
Data are expressed as mean ± SEM.
p value calculated according to Unpaired t test.
⁎ p b 0.05.
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the guidelines from Directive 2010/63/EU of the European Parliament
on the protection of animals used for scientiﬁc purposes.
2.2. Oil Red O staining
After sacriﬁce, the aortic treewere cleaned and stripped of fat on the
adventitia and ﬁxed in 4% paraformaldehyde for 24 h. Later, aortaswere
carefully opened longitudinally and pinned with small needles on a
Petri dish coated with silicon to expose the area of deﬁnable lesion
covering the luminal surface. Oil Red O staining was performed as
previously described [30]. The images were captured and the lesions
were quantitated by calculating the percentage of the total surface
area using Image J software.
The right carotid artery was macroscopically cut in three portions:
upstream region of the cast device (LSS), at cast level (high shear stressFig. 5. Treatment with diminazene increased the collagen content in aortic root and LSS-indu
induced plaques (A); OSS-induced plaques (B) and aortic sinus plaques (C) of diminazene-
nonparametric test). Data were expressed as mean ± SEM. Representative microphotographs[HSS]) and downstreamof the cast (OSS) and frozen inOCT. The LSS and
OSS portions and aortic sinus from all mice were serially cut in 7 μm
transversal sections and stained with Oil Red O as described previously
[31]. The sections were counterstained with Mayer's hemalum and
rinsed in distilled water. Quantiﬁcations were performed using the
MetaMorph software. Data were calculated as ratios of stained area on
total lesion area.
2.3. Sirius Red staining
Intraplaque collagen content was assessed as described elsewhere
[18]. Brieﬂy, 7 μmtransversal sections of carotid plaque (LSS andOSS re-
gions) and aortic sinus were rinsed with water and incubatedwith 0.1%
Sirius Red (Sigma Chemical Co, St Louis, MO) in saturated picric acid for
90 min. Sequentially, sections were rinsed twice with 5% acetic acid in
water for 10 s, then immersed in absolute ethanol three times before
clearing in xylene twice and cover-slipping. The sections were
photographed using identical exposure settings under normal light
microscopy. Intraplaque total collagen content was quantiﬁed by the
MetaMorph software. Data were calculated as percentages of stained
area on total lesion area.
2.4. Immunostaining in carotid plaques and aortic sinus
Carotid (LSS and OSS regions) and aortic sinus plaques were serially
cut in 7 μm transversal sections and stained as previously described
[31]. Eleven sections per staining (separated by 45 μm from each
other) from each mouse specimen were ﬁxed in acetone and immuno-
stained with the following speciﬁc antibodies: anti-ACE2 (dilution
5 μg/mL, Abcam, Cambridge, UK), anti-mouse CD68 (macrophages, dilu-
tion: 1:400; ABD Serotec, Dusseldorf, Germany), anti-mouse Ly6Gced plaques, but not in OSS-induced plaques. Quantiﬁcation for collagen staining in: LSS-
and vehicle-treated ApoE−/− mice. n.s.: non-signiﬁcant and *p b 0.05 (Mann–Whitney
(D).
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mouse MMP-9 (dilution: 1:60; R&D Systems), anti-mouse Ly6B.2
(neutrophils, dilution: 1:200; AbD Serotec, Kidlington, UK), rabbit
anti-mouse ADAM-17 (dilution: 10 μg/mL; Abcam, Cambridge, UK),
rat anti-mouse ICAM-1 (dilution: 1:200; Abcam, Cambridge, UK) and rab-
bit anti-mouse VCAM-1 (dilution: 1:200; Abcam, Cambridge, UK)
For the images obtained in brightﬁeld microscopy, the quantiﬁca-
tions were performed with the MetaMorph software and the data
were calculated as percentages of stained area from the total lesion
area (macrophages and MMP-9) or number of cells per millimeter
squared (neutrophils). Fluorescent images were obtained on a confocal
microscope equippedwith a digital imaging system (Carl Zeiss LSM700,
Zeiss, Baden-Württemberg, Germany) and ﬂuorescence intensity was
quantiﬁed by Image J software (NIH, Bethesda, MD, USA).2.5. Flow cytometry analysis of ICAM-1 and VCAM-1 in HVEC
HVEC (1.6 × 104 cells/well) were plated in 6-well plates and allowed
to adhere overnight. Cellswere then treatedwith controlmedium (CTL)
or diminazene (at 0.2 or 2 mg/mL) in the presence or absence of
20 ng/mL of human recombinant TNF-alpha (R&D Systems Ltd,
Abingdon, UK) for 3 h. Floating and adhering cells were collected from
culture wells by repeatedly washing and by trypsinization. Subsequently,
cellswere stainedwith propidium iodide ([PI], SigmaAldrich) to determine
cell viability, and anti-human VCAM-1/CD106-Phycoerythrin or anti-
human ICAM-1/CD54-Phycoerythrin (Pharmingen™, San Jose, CA)
according to the manufacturer's instructions. The samples were analyzed
by ﬂow cytometry with a FACS Calibur (Becton Dickinson). Ten thousandFig. 6. Diminazene decreased MMP-9 expression in aortic root and LSS-induced plaques, but
plaques (A); OSS-induced plaques (B) and aortic sinus plaques (C) of diminazene- and vehicle-
test). Data were expressed as mean ± SEM. Representative microphotographs (D).events for each sample were acquired. Results were expressed as mean
ﬂuorescence intensity.
2.6. Dosage of serum lipid proﬁle and inﬂammatory markers
Blood sampleswere collected by cardiac puncture andmaintained at
room temperature for 20 min. The serumwas sequentially obtained by
centrifugation (2500 rpm for 10 min). The lipids were measured by
photometric enzymatic reaction using commercial available kits
(glucose cat.#11447513; triglycerides cat.#12016648; total cholesterol
cat.#12016630; low-density lipoprotein cat.#03038661; high-density
lipoprotein cat.# 03030024 122; free fatty acids cat.#11383175001;
from Roche Diagnostics GmbH, Mannheim, Germany) using the chem-
istry analyzer Roche Hitachi 902 (Roche Diagnostics GmbH,Mannheim,
Germany). The assay was performed as described in the instruction
manual. The concentrations were expressed as mmol/L.
Serum cytokine levels (IFN-γ, IL-10, IL-12p70, IL-17A, IL-1β, IL-6,
IL-10, MCP-1, TNF-α, VEGF) were determined by using bead based
multiplex suspension array kits with Luminex technology on a BioPlex
(Bio-Rad, Hercules, CA, USA). The assay was performed following the
manufacturer's instructions and concentrations were expressed as
pg/mL.
2.7. Data and statistical analysis
Unpaired t test was used for all comparisons between diminazene-
and vehicle-treated mice on LSS- and OSS-induced plaques. One-way
ANOVA followed by Bonferroni post-test was used to evaluate ICAM-1not in OSS-induced plaques. Quantiﬁcation for MMP-9 immunostaining in: LSS-induced
treated ApoE−/−mice. n.s.: non-signiﬁcant and *p b 0.05 (Mann–Whitney nonparametric
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Prism software (GraphPad, San Diego, CA, USA). A value of p b 0.05 was
considered signiﬁcant and the results are expressed as mean ± SEM.
3. Results
3.1. Intraplaque ACE2 expression varies depending on the local pattern of
shear stress
ACE2 protein expression in atherosclerotic plaques was assessed by
immunostaining. We found that ACE2 was strongly expressed in the
LSS-induced plaques and aortic sinus plaques (Fig. 1A–C). Interestingly,
this enzymewasweakly expressed or even not detected in OSS-induced
plaques (Fig. 1B), indicating that ACE2 expression might be modulated
by local shear stress forces or may differ according to the intraplaque
composition and environment. No difference in ACE2 expression was
observed between diminazene or vehicle treated mice (data not
shown).
One possible explanation for the diminishing ACE2 levels in OSS-
induced plaque would be an increased shedding from the tissues by A
disintegrin andmetalloproteinase (ADAM17) [32]. ADAM17 is involved
in the shedding of several transmembrane proteins, including ACE2
[33]. Based on that, the intraplaque expression of ADAM17was evaluat-
ed and no difference was observed between LSS- and OSS-induced
plaques (Fig. 2).
Therefore, apparently, an increased expression of ADAM-17 is not
associated with the lower presence of ACE2 in OSS-induced plaques.
In order to better understand the function of ACE2 within the ath-
erosclerotic lesion, ACE2 was co-immunostained with CD68 and
Ly6B.2, speciﬁc markers for macrophage and neutrophil. It was ob-
served that ACE2 was not intensely co-localized with CD68 or Ly6B.2Fig. 7. Treatment with diminazene reduced the accumulation of macrophages in the vulnerable
plaques (A); OSS-induced plaques (B) and aortic sinus plaques (C) of diminazene- and vehicle-
test). Data were expressed as mean ± SEM. Representative microphotographs (D).(Fig. 3), suggesting that macrophage and neutrophil are not the mean
sources of ACE2 intraplaque.
3.2. Diminazene ameliorates the composition of vulnerable plaque
Lipid content within LSS-induced carotid plaques presented a ten-
dency to be reduced in the diminazene treatedmice (25% of reduction),
but no statistical signiﬁcance was observed (p = 0.308, Fig. 4A and D).
The treatment with diminazene did not alter lipid content in OSS-
induced plaque and aortic sinus (Fig. 4B, C and D). Similarly, atheroscle-
rotic lesion size in the aorta tree was not altered by diminazene treat-
ment (Table 1).
Although diminazene treatment did not signiﬁcantly alter the ath-
erosclerotic plaque lipid content and size, it did ameliorate plaque com-
position. Diminazene signiﬁcantly increased the intraplaque total
collagen content in LSS-induced and aortic sinus plaques, as compared
to the vehicle group (Fig. 5A, C and D respectively). Accordingly,
diminazene treatment resulted in a reduced MMP-9 expression in
LSS-induced plaques (Fig. 6A), but no change was observed in aortic
sinus plaques (Fig. 6C and D). Additionally, diminazene treatment de-
creased macrophage inﬁltration in LSS-induced and aortic sinus
plaques,when compared to the vehicle group (Fig. 7A, C andD). Despite
a tendency of reduced neutrophil inﬁltration in LSS-induced and aortic
sinus plaques, no statistical difference was observed (Fig. 8A–D), 32%
and 37% of reduction (p = 0.417 and p = 0.152, for LSS-induced and
aortic sinus plaques, respectively). Diminazene did not alter the
intraplaque smooth muscle content, evaluated by immunostaining for
alpha actin in aortic root plaques (data not shown).
Interestingly, none of the diminazene-mediated beneﬁcial effects on
LSS-induced and aortic sinus plaques was observed in OSS-induced
plaques. Diminazene did not change the intraplaque collagen contentplaques. Quantiﬁcation for CD68 (macrophage marker) immunostaining in: LSS-induced
treated ApoE−/−mice. n.s.: non-signiﬁcant and *p b 0.05 (Mann–Whitney nonparametric
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tion (Fig. 7B and D), and neutrophil inﬁltration (Fig. 8B and D) in OSS-
induced plaques as compared to vehicle control. These data suggest
that diminazene acts exclusively on plaques expressing ACE2 or it
actions depend on the plaque phenotype.
3.3. Diminazene reduces triglycerides serum levels but does not alter
cholesterol levels
At the end of the experiment, total cholesterol, low-density lipopro-
tein cholesterol, high-density lipoprotein cholesterol or free fatty acid
serum levels were assessed. Diminazene treatment signiﬁcantly re-
duced triglyceride serum levels. No other parameters were altered
(Table 1).
3.4. Diminazene diminishes ICAM-1 and VCAM-1 expression
To examine themechanism bywhich diminazene decreasedmacro-
phage inﬁltration, ICAM-1 and VCAM-1 expression on aortic root
plaques and HVEC, stimulated or not with TNF-α, were evaluated.
Diminazene treatment decreased intraplaque expression of ICAM-1
andVCAM-1 (Fig. 9A–J). In HVEC, diminazene at 2mg/mL reduced base-
line ICAM-1 expression when compared to control group. As expected,
TNF-α signiﬁcantly increased ICAM-1 expression on HVEC, while
diminazene abolished its effect (Fig. 9M). Of note: 1) ACE2 was well
expressed on HVEC as it was detected by western blot (Fig. 9L);
2) VCAM-1 was not detected in HVEC, even after incubation with
TNF-α; and 3) diminazene at 0.2 mg/mL did not alter ICAM-1 expres-
sion on HVEC (Fig. 9L).Fig. 8. Diminazene did not alter signiﬁcantly the accumulation of neutrophil in atheroscleroti
plaques (A); OSS-induced plaques (B) and aortic sinus plaques (C) of diminazene- and vehicl
were expressed as mean ± SEM. Representative microphotographs (D).3.5. Treatment with diminazene diminishes inﬂammation in ApoE−/−mice
The circulatory levels of key cytokines and chemokines in the ath-
erosclerotic condition were measured in the serum of diminazene-
treated and untreated mice. The long-term treatment with diminazene
signiﬁcantly reduced IL-1β, IL-6 and VEGF serum levels (Table 2). Al-
though no statistical signiﬁcance was reached, diminazene treatment
produced a strong tendency to reduce MCP-1 serum levels (p =
0.085, Table 2). Diminazene slightly reduced IFN-γ, IL-10, IL-12p70,
IL-17A, and TNF-α serum levels, but no statistical signiﬁcance was
measured (Table 2).4. Discussion
Shear stress forces are one of the main factors modulating athero-
sclerosis. These biomechanical elements inﬂuence several molecular
mechanisms and control atherosclerotic plaque composition [3–5]. In
the present study, we found that ACE2, a major enzyme of the renin an-
giotensin system,was expressed in LSS-induced atherosclerotic plaques
in the carotid artery and aortic sinus; however, poor to undetectable
expression was seen in OSS-induced plaques in the carotid artery. This
interesting ﬁnding is in keeping with previous reports indicating a
differential modulation of RAS components by distinct shear stress
patterns. It has been documented that oscillatory ﬂow induces a time-
dependent change in AT1 receptor expression on endothelial cells
[34]. Moreover, a pronounced expression of AT1 receptor on the endo-
thelial cells of the inner curvature ofmouse aortic arch (atheroprone re-
gions of the aortic arch) was found, while AT1 expression was almost
absent on the outer curvature [34]. In accordance, we have reportedc plaques. Quantiﬁcation for Ly6G (neutrophil marker) immunostaining in: LSS-induced
e-treated ApoE−/−mice. n.s.: non-signiﬁcant (Mann–Whitney nonparametric test). Data
Table 2
Serum cytokines.
Cytokines
(pg/mL)
Vehicle
(n = 19)
DIZE
(n = 15)
p-Value
IFN-γ 25.14 ± 3.143 23.28 ± 5.958 0.7654
IL-10 128.6 ± 23.58 109.9 ± 25.33 0.5924
IL-12p70 152.5 ± 21.18 126.1 ± 20.16 0.3940
IL-17 225.2 ± 17.85 185.6 ± 27.51 0.2271
IL-1B 677.2 ± 93.11 448.3 ± 22.44 0.0358⁎
IL-6 38.67 ± 7.699 19.33 ± 1.865 0.0402⁎
MCP-1 205.9 ± 19.42 165.5 ± 11.73 0.0856
TNF-α 2362 ± 212.6 2285 ± 232.5 0.8099
VEGF 1199 ± 217.3 519.4 ± 77.13 0.0180⁎
Data are expressed as mean ± SEM.
p value calculated according to Unpaired t test.
⁎ p b 0.05.
Fig. 9.Diminazene diminishes ICAM-1 and VCAM-1 expression. Quantiﬁcation and representative microphotographs of VCAM-1 and ICAM-1 staining in ApoE−/−mouse aortic roots and
HVEC: (A–B) DAPI and VCAM-1 expression in vehicle-treated mouse; (C–D) DAPI and VCAM-1 expression in diminazene-treated mouse; (E–F) DAPI and ICAM-1 expression in vehicle-
treatedmouse; (G–H)DAPI and ICAM-1 expression in diminazene-treatedmouse; quantiﬁcation of VCAM-1 (I) and ICAM-1; (J) intraplaque protein expression (*p b 0.05,Mann–Whitney
nonparametric test); L) representative gel of western blotting showing ACE2 expression on HVEC; M) ICAM-1 expression in HVEC incubated with control medium (CTL), diminazene
(at 0.2 and 2 mg/mL) with or without 20 ng/mL TNF-α. n.s.: non-signiﬁcant and ***p b 0.01 (one-way ANOVA followed by Bonferroni post-test). Data are expressed as mean ± SEM of
mean ﬂuorescence intensity.
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in the upstream regions of human plaques as compared to the down-
stream (regions with distinct patterns of shear stress) [18].
Onewell-knownmechanism responsible for local depletion of ACE2
is an augmented shedding by ADAM17 [32]. Here we observed that
ADAM17 was well expressed in both LSS- and OSS-induced plaques;
however, no difference in expression between them was observed. As
a limitation, the intraplaque activity of ADAM17 was not measured,
and despite the fact that ADAM17 expression is similar between LSS-
and OSS-induced plaques, it could be possible that this enzyme is
more active in the OSS than in the LSS region. Indeed, it has been report-
ed that ADAM17 is overactive in human carotid atherosclerotic plaques
of type 2 diabetes mellitus patients (condition associated with acceler-
ated atherosclerosis), whichwas associatedwith a decrease of tissue in-
hibitor of metalloproteinase 3, an endogenous inhibitor of ADAM17
111R.A. Fraga-Silva et al. / Vascular Pharmacology 74 (2015) 103–113[35]. Nevertheless, the mechanism by which ACE2 is poorly expressed
in OSS-induced plaques remains to be elucidated.
Interestingly, three weeks of diminazene treatment ameliorated the
composition of LSS-induced carotid and aortic sinus plaques, while it
did not affect OSS-induced carotid plaque. The ﬁrst ACE2 activator was
developed in 2008 by the group of Prof. Raizada [36]. Using a virtual
molecular docking selection strategy, 139,735 molecules (library of
the National Cancer Institute, US) were screened to access the ability
to interact with a speciﬁc pocket of ACE2 and sustain a favorable confor-
mation for optimal enzyme activity [36]. The highest scoring com-
pounds were obtained and assayed in vitro to evaluate their abilities
to enhance ACE2 catalytic activity. One of the effective compounds
was called XNT, which showed an enhanced catalytic rate by increasing
the velocity of the enzyme 2-fold [36–39]. More recently, diminazene
was identiﬁed as another ACE2 activator compound, but this time
using a library of 1217 chemicals from the Food and Drug Administra-
tion (FDA)-approved compounds, and therefore, compounds with
extensive information on bioavailability, toxicity, and safety [26].
Diminazene was ﬁrst described as an antitrypanosomal drug. This
compound was used for the treatment of early-stage sleeping sickness,
an infection caused by Trypanosoma brucei [40]. Interestingly, early
studies have shown that diminazene might produce a hypotensive
side-effect that was related to direct and indirect effects on the cardio-
vascular system [40]. Diminazene actions on the cardiovascular system
have been documented in different conditions. For instance, diminazene
attenuates pulmonary hypertension [27], reduces damages in cardiac
[41] and stroke ischemia [42], improves erectile function [43], as well
as other beneﬁcial effects [44,45].
The mechanisms by which diminazene produces beneﬁcial cardio-
vascular outcomes are not completely understood. Evidence has dem-
onstrated that diminazene acts by modifying ACE2 activity and, as a
result, decreases Ang II and increases Ang-(1–7) levels [19]. In fact, co-
administration of C-16, ACE2 inhibitor, abolished the protective effects
of diminazene on pulmonary hypertension [27] and post-myocardial
infarction [41]. Moreover, it has been shown that treatment with
diminazene (15 mg/kg/day) increased Ang-(1–7) circulating level and
enhanced endothelial function in a model of diabetes [46]. Similarly,
diminazene at 30mg/kg/day elevated plasmaAng-(1–7) concentrations
in Ldlr−/−mice [45]. Supporting these observations, co-administration
of A-779, an Ang-(1–7)-Mas receptor antagonist, attenuates the beneﬁ-
cial action of diminazene on cerebral ischemia [42] and glaucoma [44].
Additionally, diminazene may also upregulate the expression of ACE2
[27], indicating that this compound not only augments intrinsic enzyme
activity, but also increases the total enzyme expression. The relevance of
each mechanism most likely depends on the treatment condition and,
despite bothmechanisms, synergistical output to increase ACE2 activity,
it still remains to be elucidated. In our study, we observed that
diminazene acted only in atherosclerotic plaque expressing ACE2, sug-
gesting that the effects of this compound depend on ACE2. However,
as in the present study it was not possible to assess the levels of Ang II
and Ang-(1–7) within the atherosclerotic plaques, the mechanism by
which diminazene improves the plaque stability should be prudently
interpreted.
The atheroprotective actions of ACE2 have been shown in a variety
of studies. This enzyme is expressed within animal [20,22] and human
atherosclerotic plaques [21] and located in different cell types present
in the lesions, such as endothelial cells, vascular smooth muscle cells
and macrophages [14]. It has been shown that ACE2 overexpression
by gene transfer diminished lesion progression in a rabbit model of ath-
erosclerosis induced by endothelial injury and atherogenic diet [22].
Likewise, overexpression of ACE2 in ApoE−/−mice attenuates athero-
sclerotic lesion size [47], indicating a beneﬁcial role of ACE2 against
atherosclerosis development. The protective action of ACE2 on athero-
sclerosis is also supported by data on ACE2-deﬁcient mice model.
ACE2-deﬁciency in both low-density lipoprotein receptor-deﬁcient
(Ldlr−/−) and ApoE−/− backgrounds presented larger atheroscleroticlesionswhen compared to their respective controls [23–25]. In the pres-
ent study, three weeks of treatment with diminazene did not alter the
atherosclerotic lesion size. Despite apparently inconsistent data, it is
reasonable to infer that the short period of treatment was not sufﬁcient
to reduce the plaque size and/or that the pharmacological activation of
ACE2 by diminazene is less effective compared to that of gene transfer
overexpression.Nonetheless, diminazene improved the lesion composi-
tion for a more stable phenotype, diminishing the inﬁltration of inﬂam-
matory cells and increasing collagen deposition. In support of our data,
Dong and co-workers [22] showed that ACE2 overexpression enhances
plaque stability in a rabbit model of atherosclerosis by reducing macro-
phage inﬁltration, decreasing lipid deposition, lowering MMP-3 and
MMP-9 activities, and increasing collagen content. Similarly, ACE2
gene deletion increased atherosclerotic vulnerability by increasing the
intraplaque inﬂammatory proﬁle [23–25]. Therefore, the pharmacolog-
ical activation of ACE2 by diminazene appears to be consistent with the
previous studies evaluating ACE2 overexpression or deletion.
Interestingly, in the present study, we reported that diminazene ac-
tion depends on the local pattern of shear stress. In LSS and aortic sinus
plaques, diminazene increased collagen content, decreased MMP-9
expression and reduced macrophage inﬁltration, while in OSS-induced
carotid plaques, none of the studied parameters were altered. The pos-
sible lack of action in the OSS region might be due to the fact that ACE2
was poorly expressed in such plaques. It is reasonable to argue that,
since ACE2 is widely expressed in the cardiovascular system, shifting
the balance between Ang-(1–7) and Ang II, it is possible that increased
Ang-(1–7) circulating levels would modulate OSS-induced plaque
phenotype. Notwithstanding, we previously reported that long-term
treatment with Ang-(1–7) ameliorates the phenotype of LSS-induced
plaques, but did not affect OSS-induced plaques [18]. Therefore, the
probable increase in the circulating level of Ang-(1–7) via diminazene
would not affect OSS plaque composition. Despite the above specula-
tions the mechanism as to why diminazene did not affect OSS-
induced plaques still remains to be elucidated.
Here we reported that diminazene treatment signiﬁcantly reduced
the expression of ICAM-1 and VCAM-1, critical adhesion molecules on
endothelial cells favoring atherosclerosis. These results were conﬁrmed
by previous studies. For instance, deﬁciency of ACE2 increased gene ex-
pression of VCAM-1 in mouse aorta, while endothelial cells cultured
from ACE2 deﬁciency mice were characterized by increased VCAM-1
gene expression and secretion [24]. A similar effect was observed in
cells from wild-type mice treated with the selective ACE2 inhibitor,
MLN-4760 [24]. In another study, ACE2 gene transfer inhibited in vitro
the monocyte adhesion to endothelial cells, which was associated
with a reduction in VCAM-1 and E-selectin protein expression [48].
Moreover, diminazene also reduced IL-1β, IL-6 andMCP-1, putativeme-
diators of atherogenesis that enhance responsiveness to proinﬂamma-
tory stimuli. These ﬁndings are consistent with previous literature
reports [22–24]. Thomas and colleagues [24] found that deﬁciency of
ACE2 in ApoE−/−mice was associated with increased gene expression
of several inﬂammatory cytokines when compared to ApoE−/− mice,
including TNFα, IL-6 and CCL2. In another study, ACE2-deﬁciency en-
hanced accumulation of macrophages into the lesions which was asso-
ciated with an increase in proinﬂammatory markers [23]. Likewise,
overexpression of ACE2 leads to a reduction in the expression of
intraplaque inﬂammatory cytokines [22]. Interestingly, diminazene
strongly diminished VEGF levels, which is in accordance with previous
published reports [49,50]. For example, ACE2 overexpression [50] re-
duced VEGF expression in a rat model of diabetic nephropathy, while
Ang-(1–7) administration produced a similar effect [49]. VEGF is a sig-
nal protein with multipotent actions documented in vivo and in vitro;
however, its action on plaque vulnerability is not completely under-
stood [51]. In general, it is recognized that VEGF causes immature
intraplaque neovascularization highly susceptible to leakage or rupture
[52]. Together, these ﬁndings suggest that diminazene ameliorates
plaque stability parameters by inhibiting the secretion of inﬂammatory
112 R.A. Fraga-Silva et al. / Vascular Pharmacology 74 (2015) 103–113cytokines and reducingmacrophage inﬁltration. However, suchmecha-
nism still needs to be clariﬁed.
Although one might argue that diminazene may decrease blood
pressure and modify the hemodynamic proﬁle at the site of atheroscle-
rosis formation, altering the plaque development and/or composition,
previous publications indicated that diminazene does not change
blood pressure. It has been documented that diminazene reduced pul-
monary hypertension in a rat model without affecting basal systemic
blood pressure [27]. Similarly, in a rat model of kidney injury,
diminazene produced beneﬁcial outcomes without changing blood
pressure [53]. Moreover, diminazene attenuated ischemia-induced car-
diac pathophysiology and did affect systolic blood pressure [41]. These
results suggest that diminazene-mediated activity is independent on
blood pressure change. Nevertheless, as a limitation, the present study
did not assess the blood pressure of the studied animals.
5. Conclusions
ACE2 is differently expressed in atherosclerotic plaques depending
on the local pattern of shear stress forces. Treatment with diminazene,
a pharmacological ACE2 activator compound, enhances a stable pheno-
type of atherosclerotic plaques in which ACE2 is expressed. These
plaques, in the LSS region of the carotid and in aortic sinus, usually
presented a more vulnerable phenotype, suggesting a selective protec-
tive action of diminazene.
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